信达生物（01801.HK）近日发布的2025年中期业绩报告显示，公司今年上半年实现营业收入59.53亿元，同比增长50.6%，净利润达8.34亿元，成功实现扭亏为盈（去年同期净利润为-3.93亿元），毛利率提升3.1个百分点至86%。 业内人士指出，今年上半年的业绩增长，标志着信达生物“肿瘤+综合产品”的创新药双轮驱动策略进入收获期。其全球创新管线的临床突破与商业化能力的提升，有望重塑生物医药...
Source Link信达生物（01801.HK）近日发布的2025年中期业绩报告显示，公司今年上半年实现营业收入59.53亿元，同比增长50.6%，净利润达8.34亿元，成功实现扭亏为盈（去年同期净利润为-3.93亿元），毛利率提升3.1个百分点至86%。 业内人士指出，今年上半年的业绩增长，标志着信达生物“肿瘤+综合产品”的创新药双轮驱动策略进入收获期。其全球创新管线的临床突破与商业化能力的提升，有望重塑生物医药...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.